Articles published by Can-Fite BioPharma Ltd.![]() ![]() ![]()
Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming Conference
October 13, 2022
Via Business Wire
Tickers
CANF
![]() ![]() Via Business Wire
Tickers
CANF
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() Via Business Wire
Tickers
CANF
![]() ![]() ![]() ![]() Via Business Wire
Tickers
CANF
![]() Via Business Wire
Tickers
CANF
![]() ![]()
Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson
January 31, 2022
Via Business Wire
Tickers
CANF
![]() ![]() Via Business Wire
Tickers
CANF
![]() ![]() ![]() ![]() ![]() Via Business Wire
Tickers
CANF
![]()
Can-Fite’s Piclidenoson Commences Clinical Study for the Treatment of Canine Osteoarthritis
November 23, 2021
Via Business Wire
Tickers
CANF
![]()
Can-Fite to Present at H.C. Wainwright 7th Annual Israel Conference
November 12, 2021
Via Business Wire
Tickers
CANF
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|